Please check your internet connection and try again.
# Miconazole Vaginal Pessary
## Overview
Miconazole is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes. Vaginal pessaries deliver the medication directly to the vaginal mucosa.
## Primary Indications
Treatment of vulvovaginal candidiasis (yeast infections).
## Adult Dosing
* **100 mg vaginal pessary:** Insert 1 pessary vaginally at bedtime for 7 days.
* **200 mg vaginal pessary:** Insert 1 pessary vaginally at bedtime for 3 days.
* **High-strength (e.g., 1200 mg) vaginal suppository:** Insert 1 suppository vaginally at bedtime as a single dose.
Specific duration of therapy may vary based on clinical guidelines or physician discretion.
## Pediatric Dosing
* Data for safety and efficacy in pediatric populations, particularly in younger children, is limited. Use should be based on clinical judgment and may follow adult regimens if deemed appropriate by a healthcare provider.
## Dose Adjustments
No dose adjustments are necessary for renal or hepatic impairment as systemic absorption is minimal.
## Contraindications
* Hypersensitivity to miconazole or any component of the formulation.
## Adverse Effects
* **Common:** Vulvovaginal burning or irritation, itching, redness, abdominal cramps, headache.
## Key Drug Interactions
* **CYP3A4 inhibitors:** Miconazole is a moderate inhibitor of CYP3A4. Coadministration with strong CYP3A4 substrates (e.g., certain statins, calcium channel blockers, benzodiazepines, immunosuppressants) may increase the risk of adverse events related to the substrate. While systemic absorption of vaginal miconazole is low, caution is advised.
* **Warfarin:** Miconazole (especially oral) can potentiate the anticoagulant effect of warfarin. Although rare with vaginal use, monitor INR closely if used concurrently with warfarin.
## Monitoring
* Monitor for signs and symptoms of vulvovaginal candidiasis.
* Assess for and manage adverse effects.
## Clinical Pearls
* Ensure the pessary is inserted as deeply as possible into the vagina, preferably at bedtime to minimize leakage.
* Treatment may be continued during menstruation, but patients should be counselled on potential for reduced efficacy or increased leakage.
* Some formulations may interact with latex condoms and diaphragms, potentially reducing their effectiveness. Advise patients to use alternative methods of contraception during treatment.
* Recurrent infections may require longer courses of therapy or alternative treatments.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for product-specific prescribing information. Always consult the most current drug monograph and institutional protocols before prescribing.
